NASDAQ:SPHS - Sophiris Bio Stock Price, Forecast & News

Sophiris Bio's stock was trading at $0.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SPHS shares have increased by 17.4% and is now trading at $0.27. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sophiris Bio.

Sophiris Bio is scheduled to release its next quarterly earnings announcement on Wednesday, April 1st 2020. View our earnings forecast for Sophiris Bio.

Sophiris Bio Inc (NASDAQ:SPHS) issued its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. View Sophiris Bio's earnings history.

2 brokerages have issued 1 year price objectives for Sophiris Bio's stock. Their forecasts range from $2.80 to $6.00. On average, they anticipate Sophiris Bio's stock price to reach $4.40 in the next twelve months. This suggests a possible upside of 1,529.6% from the stock's current price. View analysts' price targets for Sophiris Bio.

News headlines about SPHS stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sophiris Bio earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View the latest news aboutSophiris Bio.

Some companies that are related to Sophiris Bio include Aclaris Therapeutics (ACRS), Q BioMed (QBIO), Iterum Therapeutics (ITRM), Forward Pharma A/S (FWP), Neos Therapeutics (NEOS), Soligenix (SNGX), resTORbio (TORC), Acasti Pharma (ACST), AgeX Therapeutics (AGE), Entasis Therapeutics (ETTX), Tonix Pharmaceuticals (TNXP), Heat Biologics (HTBX), CNS Pharmaceuticals (CNSP), Advaxis (ADXS) and ASLAN PHARMACEU/ADR (ASLN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), Celator Pharmaceuticals (CPXX), SLS International (SLS), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Heat Biologics (HTBX), Novavax (NVAX), Verastem (VSTM) and SCYNEXIS (SCYX).

Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SPHS stock can currently be purchased for approximately $0.27.

Sophiris Bio has a market capitalization of $9.60 million. The biopharmaceutical company earns $-6,780,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe. View additional information about Sophiris Bio.

The official website for Sophiris Bio is http://www.sophirisbio.com/.

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]